Home - Telix Pharmaceuticals

Leading a new era in radiopharmaceuticals

Telix is a global, commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.

Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.

Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide.

About Telix

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline

Clinical Pipeline

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix® and Gozellix®

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix® and Gozellix®

Learn more about Telix’s Phase III prostate cancer therapy trial.

Learn more

ProstACT Global

Learn more about Telix’s Phase III prostate cancer therapy trial.

Learn more

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Telix today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Japanese patients. The patient was dosed at Shonan Kamakura General Hospital (SKGH) in Kamakura,…

Changing the way we find and treat cancer and rare diseases

Leading a new era in radiopharmaceuticals

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Leading a new era in radiopharmaceuticals

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Subscribe